High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.05M
-6.03%
-0.244
-21.29%
6.17M
+324.29%
-0.241
-39.68%
6.17M
+453.28%
-0.242
-41%
Estimates Revision
The market is revising Downward the revenue expectations for Prime Medicine, Inc. (PRME) for FY2025, with the revenue forecasts being adjusted by -44.75% over the past three months. During the same period, the stock price has changed by 3.49%.
Revenue Estimates for FY2025
Revise Downward
-44.75%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+5.84%
In Past 3 Month
Stock Price
Go Up
+3.49%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast PRME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRME is 6.08 USD with a low forecast of 4.25 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
3 Hold
0 Sell
Moderate Buy
Current: 3.850
Low
4.25
Averages
6.08
High
9.00
Current: 3.850
Low
4.25
Averages
6.08
High
9.00
JPMorgan
Tessa Romero
Neutral
maintain
2025-11-18
Reason
JPMorgan
Tessa Romero
Price Target
2025-11-18
maintain
Neutral
Reason
JPMorgan analyst Tessa Romero kept a Neutral rating with no price target on Prime Medicine following a transfer of coverage. The firm says it would consider recommending the shares as the company moves closer to "value-creating milestones."
Citi
Samantha Semenkow
Neutral
downgrade
$5
2025-11-11
Reason
Citi
Samantha Semenkow
Price Target
$5
2025-11-11
downgrade
Neutral
Reason
Citi analyst Samantha Semenkow lowered the firm's price target on Prime Medicine to $4.25 from $5 and keeps a Neutral rating on the shares.
Citi
Neutral
maintain
$4 -> $5
2025-10-29
Reason
Citi
Price Target
$4 -> $5
2025-10-29
maintain
Neutral
Reason
Citi raised the firm's price target on Prime Medicine to $5 from $4 and keeps a Neutral rating on the shares. The firm adjusted biotech price targets as part of a Q3 earnings preview.
Citi
Buy
to
Neutral
downgrade
$10
2025-05-26
Reason
Citi
Price Target
$10
2025-05-26
downgrade
Buy
to
Neutral
Reason
Citi downgraded Prime Medicine to Neutral from Buy with a price target of $1.50, down from $10. The shares are trading near cash, reflecting the market's uncertainty on the company's path to potential value inflection, the analyst tells investors in a research note. The firm says Prime's cash runway supports operations only into the first half of 2026 after implementing cost-cutting measures, which is well short of management's guidance of initial in-vivo clinical data for Wilson's and Alpha-1 antitrypsin deficiency in 2027.
Citizens JMP
Silvan Tuerkcan
Outperform
to
Outperform
downgrade
$10 -> $6
2025-05-20
Reason
Citizens JMP
Silvan Tuerkcan
Price Target
$10 -> $6
2025-05-20
downgrade
Outperform
to
Outperform
Reason
Citizens JMP analyst Silvan Tuerkcan lowered the firm's price target on Prime Medicine to $6 from $10 and keeps an Outperform rating on the shares. Prime Medicine is focusing its efforts on high-value in-vivo opportunities, Wilson's disease and Alpha-1 Antitrypsin Deficiency, and is making changes to management and the company, with Allain Reine taking over the CEO role from Keith Gottesdiener, who will remain as a consultant, while Jeff Marrazzo was appointed Executive Chair, the analyst tells investors in a research note. Citizens views the removal of Chronic Granulomatous Disease as a sensible decision, given the backdrop of ex-vivo cell therapy launches, large opex requirements, and the small patient population.
H.C. Wainwright
Arthur He
Buy -> Neutral
downgrade
2025-05-20
Reason
H.C. Wainwright
Arthur He
Price Target
2025-05-20
downgrade
Buy -> Neutral
Reason
H.C. Wainwright analyst Arthur He downgraded Prime Medicine to Neutral from Buy without a price target. The company decided to discontinue the development of PM359 for the treatment of chronic granulomatous disease as well as the X-linked CGD program, while focusing on its in vivo liver franchise including PM577 for Wilson's Disease and recently unveiled alpha-1 antitrypsin deficiency program, the analyst tells investors in a research note. The firm is surprised by Prime's decision and now sees financial and legal uncertainties as well as a lack of catalysts for the shares.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Prime Medicine Inc (PRME.O) is -3.96, compared to its 5-year average forward P/E of -4.91. For a more detailed relative valuation and DCF analysis to assess Prime Medicine Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.91
Current PE
-3.96
Overvalued PE
-2.13
Undervalued PE
-7.70
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-4.07
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.73
Undervalued EV/EBITDA
-7.41
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
138.17
Current PS
0.00
Overvalued PS
348.32
Undervalued PS
-71.98
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 18302.86% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 18302.86% over the last month.
Sold
Bought
PRME News & Events
Events Timeline
(ET)
2025-11-07
07:05:22
Prime Medicine Announces Q3 Earnings Per Share of 32 Cents, Exceeding Consensus Estimate of 25 Cents
2025-11-03 (ET)
2025-11-03
08:04:42
Prime Medicine names Hawryluk as Chief Business Officer
2025-08-07 (ET)
2025-08-07
08:05:00
Prime Medicine reports Q2 EPS (41c), consensus (34c)
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/aa9d11ed7b1e2bce5c6b8394d024cce6c7148d3a40054798609104e53716ad29.png)
Preview
1.0
11-11NewsfilterPrime Medicine to Showcase at Jefferies Global Healthcare Conference
Preview
4.0
11-10BenzingaChardan Capital Keeps Buy Rating on Prime Medicine, Reduces Price Target to $9
Preview
9.5
11-07NewsfilterPrime Medicine Announces Financial Results for Q3 2025 and Shares Business Developments
Sign Up For More News
People Also Watch
FAQ
What is Prime Medicine Inc (PRME) stock price today?
What is Prime Medicine Inc (PRME)'s business?
What is the price predicton of PRME Stock?
What is Prime Medicine Inc (PRME)'s revenue for the last quarter?
What is Prime Medicine Inc (PRME)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Prime Medicine Inc (PRME)'s fundamentals?
How many employees does Prime Medicine Inc (PRME). have?